Sentences with phrase «with leukemia at»

Chan's son was diagnosed with leukemia at three years old.

When he was first diagnosed with leukemia at age 9, Dominick just wanted to get well, so he could play sports again.

Not exact matches

As her dying wish, 8 - year - old Delaney Brown, who was diagnosed with leukemia in 2013, wanted to see Christmas carolers at her door.

Not three months later, I stood with her in the hospital, 38 - weeks pregnant with her third son, while her first son was diagnosed with Leukemia, unexpectedly fighting for his life at age six.

At the age of 19, I was diagnosed with leukemia and treated with chemo and a bone marrow transplant from my sister.

Some of Walsh's former players, including Pro Bowl tight end Russ Francis, recently met with him to discuss the possibility of his undergoing experimental treatments that could theoretically keep the leukemia at bay for a prolonged period.

A few years earlier, visiting the Pediatrics Unit at Musgrove Park Hospital in Taunton, he had been genuinely overwhelmed at seeing kids the same age as his own dying of leukemia, and on a walking tour later on in the Lake District with his wife he had had the idea of this marathon hike to raise money for a leukemia research charity.

Prior to Elle's nine years at the NMSS, she held roles with with LiveSTRONG and the Leukemia Lymphoma Society Team in Training program.

These studies are at risk for selection bias both of cases and of control individuals and their results might be influenced by potential confounders such as other health behaviors that may be independently associated both with breastfeeding and childhood leukemia risk, although this is of course not limited to case - control studies.

In this meta - analysis of published (1995 - 2011) case - control studies examining the relationship between breastfeeding and childhood leukemia, all analyses, except the subanalysis for AML alone, which was not statistically significant, showed that being breastfed for at least 6 months compared with less than that or not at all was significantly associated with a 14 % to 20 % lower risk for childhood leukemia, with a 20 % lower risk when all selected 17 studies were included in the analysis.

Specifically, «The bill expands coverage to volunteer firefighters with at least five years of service who developed lymphoma or leukemia after their service, and coverage for volunteer firefighters with at least 10 years of service who develop stomach, skin, breast, prostate and other reproductive cancers after their service,» according to information from Senator Jacobs» office.

That's how Charles Sawyers, a 2009 Lasker Award winner and chair of human oncology and pathogenesis at Memorial Sloan - Kettering Cancer Center in New York City, made the connection with Bristol Myers Squibb (BMS) that led to second - generation treatments for chronic myeloid leukemia (CML).

June, a professor in immunotherapy at the University of Pennsylvania, described recent triumphs in cancer research that have now been used to treat more than 300 children with leukemia, all of whom remain in remission.

Tests showed that combining mTOR inhibitors with chemotherapy was far more effective at treating leukemia than when the inhibitors or chemotherapy were used as stand - alone treatments.

Carlo La Vecchia (MD), Professor at the Faculty of Medicine, University of Milan (Italy), one of the study authors, said: «Predictions of death rates from leukemia are complicated by the fact that leukemias are a varied collection of blood cancers, with some being more treatable than others.

«Dr. Rassool and her colleagues have identified an exciting new mechanism for attacking cancer that may ultimately provide a new option for treating patients with leukemia and other cancers,» says E. Albert Reece, MD, PhD, MBA, vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and dean of UMSOM.

Technically we can not say that we saved his life, because patients with leukemia can relapse at any time.

Public banks will accept a sample earmarked for a family with a child at high risk of leukemia or lymphoma, for instance.

«Our partnership with families who have a child with Down syndrome and our investment in a comprehensive clinical data and biorepository will continue to provide resources to study not only heart defects, but also other Down - syndrome associated medical conditions such as cognitive function, leukemia, and dementia,» says co-author Stephanie Sherman, PhD, professor of human genetics at Emory University School of Medicine.

A farmer all his life, Valencia retired at age 80 when he was diagnosed with leukemia, but it barely slowed him down.

Collaborating with coauthor Jeremy Sanford of UC Santa Cruz, the team looked closely at the role IGF2BP3 played within the leukemia cells.

Summers and the research team, led by Dr. Mike Jensen at the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroy cancer.

Both illnesses have given me a sense of the importance of the work we do at the N.I.H. I have, for instance, the feeling that kids growing up today with my family's genetic history won't get leukemia when they reach my age.

After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

«We're at a pivotal point where we're building upon what we've learned in the PLAT - 02 trial and opening new trials, like PLAT - 04, with the goal of improving this therapy to the point that it becomes a long - term cure for all of our leukemia patients,» said Dr. Corinne Summers, an oncologist at Seattle Children's and the lead investigator of the PLAT - 04 trial.

Epidemiologists at University of California, San Diego School of Medicine report that persons residing at higher latitudes, with lower sunlight / ultraviolet B (UVB) exposure and greater prevalence of vitamin D deficiency, are at least two times at greater risk of developing leukemia than equatorial populations.

For instance, researchers at the Salk Institute in California have taken skin cells from a patient with the genetic disease Fanconi's anemia, often associated with leukemia.

If so, says Grover Bagby, a hematologist who directs the Oregon Cancer Center at the Oregon Health Sciences University in Portland, further work to decipher the protein's exact function could shed light on how to treat a much larger population of patients with leukemia, certain other forms of cancer, and aplastic anemia.

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical «signature» in blood - forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

Leukemia researchers at Princess Margaret Cancer Centre have developed a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard trLeukemia researchers at Princess Margaret Cancer Centre have developed a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard trleukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard trleukemia (AML) will respond to standard treatment.

An interdisciplinary research team at The Saban Research Institute of Children's Hospital Los Angeles has found that body mass index (BMI) is an inadequate method for estimating changes in body fat and obesity in children with leukemia.

«These people are born with a broken gene and it sets them up for leukemia,» says Chris Porter, MD, investigator at the CU Cancer Center and associate professor in the Department of Pediatrics at the CU School of Medicine.

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified RNA - based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia (sAML), a particularly problematic disease that typically afflicts older patients who have often already experienced a bout with cancer.

«Our approach represents a different way of looking at leukemia and considers the entire bone marrow as an ecosystem, rather than the traditional approach of studying and trying to directly kill the diseased cells themselves,» said Allison Boyd, postdoctoral fellow with the research institute and first author of the study.

Research carried out at the Division of Genetics at Friedrich - Alexander - Universität Erlangen - Nürnberg (FAU) with support from the Institute for Human Genetics has now discovered another molecular cause for a particularly aggressive type of leukemia in infants.

She ultimately chose to study leukemia patients» immune responses to bone marrow transplants, an area conducive to translational research in part because the work involves treating patients with human cells, which can be prepared at academic health centers.

Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania.

«The lifetime risk of these cancers is fairly low - about one in 20 men and women will be diagnosed with lymphoma, leukemia, or myeloma at some point during their lifetime — so people born to older fathers should not be alarmed,» said Dr. Teras.

(TORONTO, Canada — Dec. 7, 2016)-- Leukemia researchers at Princess Margaret Cancer Centre have developed a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard trLeukemia researchers at Princess Margaret Cancer Centre have developed a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard trleukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard trleukemia (AML) will respond to standard treatment.

Using a novel technique to genetically modify T cells for adoptive transfer, Carl June, Michael Kalos, David Porter, Bruce Levine, and colleagues at the University of Pennsylvania School of Medicine achieve clinical responses in patients with chronic lymphocytic leukemia, including two complete, durable (one year) clinical responses, accompanied by in vivo expansion and long - term functional persistence of gene - modified cells.

CRI establishes the Veterinary Cancer Unit, led by William D. Hardy Jr., at the ASPCA Hospital, to deal with questions of leukemia and other cancers in animals.

The FDA granted approval to a new, first - in - class immunotherapy — tisagenlecleucel (Kymriah, Novartis)-- for the treatment patients up to 25 years old with B cell acute lymphoblastic leukemia (B - ALL) that is refractory or has relapsed after at least two previous treatments.

Hungerford, a predoctoral fellow, was writing his doctoral thesis on chromosomes in a genetics lab at Fox Chase Cancer Center, and detected a tiny flaw in chromosomes from the blood cells of patients with a type of leukemia.

The FDA granted approval to ofatumumab (ARZERRA), a targeted antibody against CD20, for patients with chronic lymphocytic leukemia (CLL) who are in complete or partial response after at least two lines of therapy.

Removal of a fifth course of chemotherapy containing cytarabine resulted in worse overall survival and disease - free survival in pediatric patients with low - risk acute myeloid leukemia (AML), according to the results (abstract 10515) of a pooled analysis of two Children's Oncology Group (COG) trials presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago.

«Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123 - Specific CAR T Cells: A First - in - Human Clinical Trial» is presented at the ASH Annual Meeting Dec. 9 to 12, 2017.

UT Southwestern, along with colleagues at seven other academic medical centers and The Leukemia & Lymphoma Society, is enrolling patients 60 and older with newly diagnosed AML in the Master Protocol for Biomarker - Based Treatment of AML (Beat AML) trial.

2/12/2008 Gene Therapy Protocol at UCSD Activates Immune System in Patients with Leukemia A research team at the Rebecca and John Moores UCSD Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies tLeukemia A research team at the Rebecca and John Moores UCSD Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies tleukemia (CLL) who were treated with a gene therapy protocol began making antibodies that r...

«Thanks to improvements in the understanding of AML biology, a multiplicity of so - called targeted therapies and therapies based on differential pathophysiology of leukemic stem cells compared with normal counterparts have emerged,» noted Richard M. Stone, MD, clinical director of the Adult Leukemia Program at Dana - Farber Cancer Institute in Boston, and colleagues, writing in a review for the ASCO 2017 Educational Book.

Dr. Sucheston - Campbell will present a companion presentation based on this research, «Functional Genetic Variants on 14q32 Associate with Death Due to Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) within One Year after HLA - Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY - BMT Study),» on Saturday, Feb. 25, 6 p.m. at Gaylord Palms Convention Center, Florida Hall C. Dr. Hahn is senior author of that presentation.